Oculis Holding AG (NASDAQ:OCS - Get Free Report)'s stock price gapped up prior to trading on Friday . The stock had previously closed at $16.93, but opened at $17.64. Oculis shares last traded at $17.45, with a volume of 51,109 shares traded.
Analysts Set New Price Targets
Separately, HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Oculis in a research note on Monday, November 11th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Oculis has an average rating of "Buy" and an average target price of $29.20.
Get Our Latest Analysis on Oculis
Oculis Price Performance
The company has a market capitalization of $711.25 million, a price-to-earnings ratio of -9.10 and a beta of -0.33. The stock has a fifty day simple moving average of $16.32 and a 200-day simple moving average of $13.72. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02.
About Oculis
(
Get Free Report)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Further Reading
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
